Research menu
Jump to menu

Publications:  Dr Helen Le Dieu

Rezvani K, Kanfer EJ, Marin D, Gabriel I, Rahemtulla A, Taylor A, Macdonald D, Dazzi F et al.(2012). EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedure. Biol Blood Marrow Transplant vol. 18, (2) 235-240.
O'Riain C, O'Shea DM, Yang Y, Le Dieu R, Gribben JG, Summers K, Yeboah-Afari J, Bhaw-Rosen L et al.(2009). Array-based DNA methylation profiling in follicular lymphoma. Leukemia vol. 23, (10) 1858-1866.
Le Dieu R, Taussig D, Ramsay AG, Mitter R, Lee AM, Lister TA, Gribben JG(2009). Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood vol. 114, (18) 3909-3916.
Le Dieu R, Taussig D, Lister TA, Gribben JG(2009). Negative immunomagnetic selection of T cells from peripheral blood of presentation AML specimens. Journal of Immunological Methods vol. 348, (1-2) 95-100.
Gorgun G, Ramsay AG, Holderried TAW, Zahrieh D, Le Dieu R, Liu F, Quackenbush J, Croce C et al.(2009). E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. PNAS vol. 106, (15) 6250-6255.
Le Dieu R, Ramsay AG, Taussig D, Mitter R, Gribben JG (2008). Differential Gene Expression Profile Identifies the Nature of T Cell Defects in AML Patients at Diagnosis. Blood. vol. 112, 1186-1186.
Ramsay AG, Johnson AJ, Lee AM, Gorgün G, Le Dieu R, Blum W, Byrd JC, Gribben JG(2008). Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest vol. 118, (7) 2427-2437.
Le Dieu R, Gribben JG(2008). Chronic Lymphocytic Leukaemia. Hematopoietic Stem Cell Transplantation, Editors: Soiffer, RJ, Edition. 1, Springer
Le Dieu R, Taussig D, MacDougal F, Lister A, Gribben JG (2007). CD3+/CD56+cells, but not natural killer T cells, are increased in peripheral blood of untreated patients with leukemia. BLOOD. vol. 110, 538A-538A.
Le Dieu R, Gribben JG(2007). Transplantation in chronic lymphocytic leukemia. Current Hematologic Malignancy Reports vol. 2, (1) 56-61.
Sekhar M, Narat S, Le Dieu R, Luqmani A, Hollamby S, Alobaidi M, Hughes G (2006). Major obstetric haemorrhage in late termination of pregnancy in eight women. BLOOD. vol. 108, 89B-90B.
Le Dieu R, Gribben J(2006). Vaccine- and immune-based therapy in chronic lymphocytic leukemia. SEMIN ONCOL vol. 33, (2) 220-229.
Le Dieu R, Gribben JG(2006). Allogeneic Stem Cell Transplantation for Non-Hodgkin's and Hodgkin's Lymphoma. The lymphomas, Editors: Canellos, GP, Lister, TA, Young, BD, Edition. 2, W B Saunders Co
Le Dieu R, Gribben J(2005). CD40 activation: lessons for HIV immunotherapy from malignancies?. J HIV Ther vol. 10, (3) 51-55.
Ledieu R, Gorgun G, Gribben J (2005). In vivo demonstration of donor idiotype specific T cells that kill primary CLL cells post allogeneic transplant. Conference: ASH from: 11/2005
Le Dieu R, Bua M, Andreasson C, Olavarria E, Goldman JM, Apperley JF, Maria D (2004). Homoharringtonine in combination with imatinib for patients with CML who have achieved partial or complete cytogenetic responses. BLOOD. vol. 104, 289A-289A.
Le Dieu R, Luckit J, Sundarasun M(2003). Complications of trephine biopsy. Br J Haematol vol. 121, (6)
Smith J, Goldsmith C, Ward A, LeDieu R(2000). IGF-II ameliorates the dystrophic phenotype and coordinately down-regulates programmed cell death. Cell Death and Differentiation vol. 7, (11) 1109-1118.
Return to top